Endocrinology

Original New Drug Application Approvals by US FDA (16-31 January 2023)

31 Jan 2023

New drug applications approved by US FDA as of 16-31 January 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Bionic pancreas better controls glucose levels than standard care in T1D

Roshini Claire Anthony, 31 Jan 2023

Insulin delivery via a bionic pancreas better controlled HbA_1clevels compared with standard of care (SoC) in patients with type 1 diabetes (T1D), according to a recent multicentre trial from the US.

Prof Ronald Ma, Prof Juliana Chan and Prof Andrea Luk

Prediabetes in youngsters linked to a nearly 80 percent increased risk of CVD

Kanas Chan, 30 Jan 2023

Prediabetes in youngsters is associated with an 88 percent lifetime risk of diabetes and a nearly 80 percent higher risk of cardiovascular disease (CVD), researchers from the Chinese University of Hong Kong (CUHK) have reported.

Diabetes status may influence long-term survival in metastatic breast cancer

Diabetes linked to elevated serum neurofilament light chain levels

28 Jan 2023

A recent study has found an association between diabetes mellitus and higher serum neurofilament light chain (sNfL), biomarkers of neuroaxonal injury in multiple neurological diseases, in a US population.

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

Elvira Manzano, 04 Oct 2022

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

$Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum$

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

14 Jan 2022

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

18 Nov 2021

Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.

Beta-blocker shows potential for diabetic foot ulcers

Audrey Abella, 20 Oct 2022

A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).

Sotagliflozin may offer cardiorenal protection for adults with T1D

Audrey Abella, 13 Oct 2022

Using the Steno T1 Risk Engines, the dual SGLT*1 and SGLT2 inhibitor sotagliflozin showed potential in reducing the risk of cardiovascular (CV) and renal disease in adults with type 1 diabetes (T1D).

Triple-drug combo reduces HbA1c in T2D

Elaine Soliven, 12 Oct 2022

Adding evogliptin, a novel dipeptidyl peptidase-4 inhibitor, to dapagliflozin and metformin significantly reduced HbA_1c level in patients with uncontrolled type 2 diabetes (T2D), according to a study presented at EASD 2022.

Young age at diabetes diagnosis tied to worse outcomes

Does age at diagnosis affect diabetes outcomes?

Roshini Claire Anthony, 09 Oct 2022

Individuals who are diagnosed with type 2 diabetes (T2D) at age ≤40 years have a greater risk of cardiovascular disease (CVD) and mortality than same-aged individuals without T2D or individuals diagnosed with T2D in later life, according to a study from Korea presented at EASD 2022.

Tirzepatide confers renal protection in patients with T2D

Elaine Soliven, 05 Oct 2022

Once-weekly injection of tirzepatide, a dual GIP and GLP-1 receptor antagonist, slowed eGFR* decline and reduced UACR** in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular (CV) disease compared with once-daily insulin glargine (iGlar), according to a prespecified post hoc analysis of the SURPASS-4*** trial presented at EASD 2022.